Mitsubishi UFJ Trust & Banking Corp Takes $1.44 Million Position in Elanco Animal Health Incorporated $ELAN

Mitsubishi UFJ Trust & Banking Corp bought a new position in shares of Elanco Animal Health Incorporated (NYSE:ELAN) during the third quarter, according to its most recent Form 13F filing with the SEC. The fund bought 71,674 shares of the company’s stock, valued at approximately $1,444,000.

A number of other large investors have also added to or reduced their stakes in the business. Arkadios Wealth Advisors lifted its holdings in Elanco Animal Health by 7.0% during the 3rd quarter. Arkadios Wealth Advisors now owns 52,216 shares of the company’s stock valued at $1,052,000 after purchasing an additional 3,434 shares during the last quarter. Wealth Enhancement Advisory Services LLC raised its position in shares of Elanco Animal Health by 41.3% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 16,277 shares of the company’s stock valued at $333,000 after purchasing an additional 4,761 shares during the period. Amalgamated Bank lifted its stake in shares of Elanco Animal Health by 793.7% during the 3rd quarter. Amalgamated Bank now owns 226,580 shares of the company’s stock worth $4,563,000 after buying an additional 201,226 shares during the last quarter. Resonant Capital Advisors LLC boosted its holdings in shares of Elanco Animal Health by 3.4% during the 3rd quarter. Resonant Capital Advisors LLC now owns 32,823 shares of the company’s stock worth $661,000 after buying an additional 1,090 shares during the period. Finally, Sequoia Financial Advisors LLC boosted its holdings in shares of Elanco Animal Health by 19.4% during the 3rd quarter. Sequoia Financial Advisors LLC now owns 20,770 shares of the company’s stock worth $418,000 after buying an additional 3,374 shares during the period. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Down 0.6%

NYSE ELAN opened at $24.05 on Friday. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. The company has a market cap of $11.95 billion, a price-to-earnings ratio of 400.90, a PEG ratio of 3.38 and a beta of 1.87. The company has a 50 day moving average of $23.02 and a 200-day moving average of $20.31. Elanco Animal Health Incorporated has a 1-year low of $8.02 and a 1-year high of $25.29.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings results on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The business had revenue of $1.14 billion for the quarter, compared to the consensus estimate of $1.09 billion. During the same quarter in the prior year, the business posted $0.13 earnings per share. The firm’s quarterly revenue was up 10.4% compared to the same quarter last year. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. On average, equities research analysts expect that Elanco Animal Health Incorporated will post 0.91 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several brokerages have issued reports on ELAN. Piper Sandler upgraded shares of Elanco Animal Health from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $24.00 to $30.00 in a research report on Thursday, January 22nd. Zacks Research lowered Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research note on Thursday, November 6th. Morgan Stanley lifted their price target on Elanco Animal Health from $18.00 to $22.00 and gave the stock an “equal weight” rating in a report on Thursday, December 18th. Barclays assumed coverage on Elanco Animal Health in a research note on Tuesday, December 9th. They issued an “overweight” rating and a $30.00 price target for the company. Finally, Wall Street Zen raised Elanco Animal Health from a “buy” rating to a “strong-buy” rating in a report on Monday, January 19th. One investment analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $25.44.

Insider Buying and Selling

In related news, Director Lawrence Erik Kurzius purchased 10,000 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The shares were bought at an average price of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the transaction, the director owned 131,773 shares of the company’s stock, valued at approximately $2,806,764.90. This trade represents a 8.21% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Jeffrey N. Simmons purchased 22,000 shares of the company’s stock in a transaction that occurred on Thursday, December 11th. The stock was bought at an average cost of $21.75 per share, with a total value of $478,500.00. Following the purchase, the chief executive officer owned 167,000 shares of the company’s stock, valued at $3,632,250. This represents a 15.17% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. In the last 90 days, insiders purchased 43,450 shares of company stock valued at $937,883. Company insiders own 0.89% of the company’s stock.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.